Navigation Links
Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
Date:9/23/2008

ch and Development for Arisyn. "The compounds have proven efficacy and safety in preclinical studies and have shown significant promise to progress to Phase 1 human clinical trials for the treatment of HIV and cancer."

The continued preclinical and clinical development of the compound portfolio will be performed by ImQuest BioSciences, a Contract Research Organization located in Frederick, MD specializing in the development of drugs for the treatment of infectious disease and cancer. ImQuest will perform necessary preclinical and clinical studies and manage the evaluation of Arisyn's compounds in human clinical trials, as well as assist Arisyn with the discovery of next generation inhibitors of the novel therapeutic targets.

Bo Statham, UTR Manager, said he is very pleased that this promising technology has been assigned to Arisyn, a company that will focus exclusively on the development of these drugs.

About UTR

UTR is a limited liability company that was established to benefit the University of Arizona in the development of patents and other technology and to license or otherwise transfer such intellectual property to third parties.

About Arisyn Therapeutics Inc.

Arisyn Therapeutics Inc. is a privately held biotechnology company focused on the clinical development of small molecule therapeutics for infectious diseases and cancer. Arisyn's strategy is to develop novel inhibitors with unique mechanisms of action for chronic diseases without effective therapeutic options such as HIV, hepatitis, and cancer. Arisyn Therapeutics Inc. is based in Frederick, Maryland and is on the web at http://www.Arisyn.com.

About ImQuest BioSciences, Inc.

ImQuest BioSciences, a privately held U.S. company located in Frederick, Maryland is a leading provider of anti-infective therapeutic and microbicide development and anti-cancer services to the biotechnology and pharmaceutical ind
'/>"/>

SOURCE Arisyn Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... MADISON, N.J., Nov. 20 At a meeting of the ... today, a dividend of fifty cents($0.50) per share on the ... 2009 to stockholders of record at the close of business,on ... Wyeth is one of the world,s largest research-driven pharmaceutical and,health ...
... SIAL ),announced today the global release of MISSION(R) ... QUALITY and iScale Oligos(TM) siRNA are,expected to allow researchers ... with the highest purity and quality siRNA required for ... be well suited to target,validation and pre-clinical siRNA testing. ...
... 20 Nephros, Inc. (Amex: NEP ), a medical device company developing ... an update on its operations and strategy. , , ... , Appointed James Scibetta ... Ernest Elgin III President and CEO , Submitted ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7
(Date:4/24/2014)... fungus could now be treated in three days, rather than ... , Cryptococcus a form of yeast - ... research. They are found in many parts of the ... affect people with weakened immune systems. This infection kills up ... has tested the effects of the most commonly used drug ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
(Date:4/24/2014)... of clear liquid can bend light, acting as a ... developed a new process to create inexpensive high quality ... , Because they,re so inexpensive, the lenses can ... to detect diseases in the field, scientific research in ... in classrooms. , "What I,m really excited about ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Amazon rainforest survey could improve carbon offset schemes 2Bake your own droplet lens 2Bake your own droplet lens 3
... While researching methods to increase the already well-recognized ... Illinois also found a way to prolong the vegetable,s ... study, the method is a natural and inexpensive way ... and won,t spoil so quickly on your refrigerator shelf. ...
... disease is the most common form of birth defect, ... the National Institutes of Health. Researchers from the University ... treat laboratory mice with one form of congenital heart ... caused by abnormally thick muscle. By suppressing a faulty ...
... vegetables are associated with higher Body Mass Index (BMI) ... to American University researchers in the journal Pediatric ... between the prices of fruit and vegetables and higher ... and assistant professor of public administration and policy at ...
Cached Biology News:Better broccoli, enhanced anti-cancer benefits with longer shelf life 2Better broccoli, enhanced anti-cancer benefits with longer shelf life 3Compound improves cardiac function in mice with genetic heart defect, MU study finds 2High cost of fruits, vegetables linked to higher body fat in young children 2
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... Probes intensely fluorescent and highly photostable ... use in a variety of applications ... strong signal. Unfortunately, protein- and other ... may cause them to bind to ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Description: Proteinase K is a highly active and ... applications purified from the fungus T. album. It ... of N-substituted hydrophobic aliphatic and aromatic amino acids ... protease. Proteinase K is useful in purifying high ...
Biology Products: